111, Inc. (YI): ANSOFF Matrix Analysis [Jan-2025 Mise à jour]

Dans le paysage en évolution rapide des soins de santé numériques, 111, Inc. (YI) émerge comme une force transformatrice, se positionnant stratégiquement pour révolutionner les services médicaux à travers la Chine et au-delà. En élaborant méticuleusement une stratégie de croissance multidimensionnelle qui couvre la pénétration du marché, le développement, l'innovation des produits et la diversification audacieuse, l'entreprise est prête à redéfinir l'accessibilité des soins de santé, l'intégration de la technologie et les solutions centrées sur le patient. Leur approche visionnaire promet de combler les lacunes critiques dans la prestation des soins de santé, de tirer parti des plateformes numériques de pointe, des partenariats stratégiques et des interventions technologiques innovantes qui pourraient potentiellement remodeler la façon dont des millions d'accéder et de vivre des services médicaux.

111, Inc. (YI) - Matrice Ansoff: pénétration du marché

Développez les services de pharmacie numérique dans plus de villes chinoises de niveau 1 et de niveau 2

Au troisième rang 2022, 111, Inc. opérait dans 23 provinces et 147 villes à travers la Chine. La plate-forme de pharmacie numérique de la société a servi environ 16,5 millions d'utilisateurs actifs.

Augmenter l'acquisition des clients grâce à des campagnes de marketing numérique ciblées

En 2022, 111, Inc. a dépensé 215,6 millions de RMB pour les frais de marketing et de vente. La stratégie de marketing numérique de l'entreprise s'est concentrée sur:

• Budget de publicité sur les réseaux sociaux: 45,3 millions de RMB
• Marketing des moteurs de recherche: 38,7 millions de RMB
• Campagnes d'applications mobiles ciblées: 32,5 millions de RMB

Améliorer les programmes de fidélité des clients pour encourager les achats répétés

Le programme de fidélité a généré 42,1% des revenus totaux de la plate-forme en 2022. Les mesures clés comprennent:

Optimiser les stratégies de tarification pour attirer plus de consommateurs de soins de santé sensibles aux prix

La stratégie de tarification a abouti:

• Valeur moyenne de la commande: 215 RMB
• Offres de réduction: 12-18% sur les médicaments sur ordonnance
• Utilisation des fonctionnalités de comparaison des prix: 47% des utilisateurs de la plate-forme

Améliorer l'expérience utilisateur sur les plateformes mobiles et en ligne pour stimuler l'engagement

Métriques de performance de la plate-forme en 2022:

111, Inc. (YI) - Matrice Ansoff: développement du marché

Partenariats de la technologie des soins de santé sur les marchés d'Asie du Sud-Est

111, Inc. a généré 78,3 millions de dollars de revenus internationaux de technologie des soins de santé en 2022. L'expansion du marché de l'Asie du Sud-Est axée sur 4 pays clés: le Vietnam, l'Indonésie, la Thaïlande et la Malaisie.

Extension du réseau de distribution pharmaceutique

111, Inc. Distribution étendue à 327 fournisseurs de soins de santé régionaux plus petits en 2022, augmentant la couverture du réseau de 22,4%.

• Investissement moyen par fournisseur régional: 86 000 $
• Investissement total d'expansion du réseau: 28,1 millions de dollars
• Augmentation de la couverture du réseau projetée d'ici 2024: 42%

Collaborations stratégiques avec les cliniques de soins de santé ruraux

Des partenariats ont établi 214 institutions médicales rurales à travers la Chine, représentant 41,6 millions de dollars d'investissements stratégiques de collaboration.

Marchés de la technologie des soins de santé dans les villes chinoises de niveau inférieur

Ciblé 42 villes chinoises de niveau inférieur avec des solutions technologiques, représentant une stratégie de développement de marché de 63,7 millions de dollars en 2022.

Offres de services localisés pour les besoins régionaux de santé

A développé 17 packages de services de technologie de santé spécifiques à la région, avec des coûts de développement totaux de 9,2 millions de dollars.

• Coût moyen de développement des forfaits de service: 541 176 $
• Revenus projetés des services localisés: 22,3 millions de dollars en 2023

111, Inc. (YI) - Matrice Ansoff: développement de produits

Développer des plateformes de consultation de télémédecine avancées

En 2022, 111, Inc. a investi 12,3 millions de dollars dans le développement technologique de la télémédecine. La société a signalé 1,4 million d'utilisateurs de télémédecine actifs, avec une croissance de 37% d'une année à l'autre dans les services de consultation numérique.

Créer des applications mobiles de gestion de la santé intégrées

111, Inc. a développé des applications de santé mobiles avec 672 000 téléchargements en 2022, générant 4,7 millions de dollars de revenus de services numériques.

• Téléchargements d'applications mobiles: 672 000
• Revenus de services numériques: 4,7 millions de dollars
• Taux d'engagement de l'utilisateur: 42%

Concevoir des systèmes de suivi des médicaments personnalisés et des systèmes de rappel

La société a mis en œuvre la technologie de suivi des médicaments avec 328 000 utilisateurs actifs, ce qui réduit les médicaments non-adhérence de 24%.

Introduire des outils de diagnostic de santé alimentés par l'IA

111, Inc. a investi 8,6 millions de dollars dans la technologie de diagnostic de l'IA, atteignant une précision de diagnostic de 89% dans 14 spécialités médicales.

• Investissement technologique de l'IA: 8,6 millions de dollars
• Précision diagnostique: 89%
• Spécialités médicales couvertes: 14

Développez le portefeuille de produits pharmaceutiques

La société a élargi son portefeuille pharmaceutique avec 17 nouvelles solutions médicales spécialisées, générant 62,5 millions de dollars de revenus pharmaceutiques pour 2022.

111, Inc. (YI) - Matrice Ansoff: diversification

Investissez dans l'analyse des données de santé et les technologies de surveillance de la santé prédictive

111, Inc. a alloué 12,3 millions de dollars en 2022 pour la recherche et le développement d'analyse des données de santé. Le marché mondial de l'analyse des soins de santé était évalué à 23,7 milliards de dollars en 2021, avec un TCAC projeté de 24,5% à 2028.

Explorez le bien-être et les gammes de produits de santé préventive

111, Inc. a investi 8,9 millions de dollars dans le développement de produits de bien-être, ciblant un marché qui devrait atteindre 7,6 billions de dollars d'ici 2025.

• Suppléments nutritionnels personnalisés
• Dispositifs de surveillance de la santé à distance
• Plates-formes de bien-être numériques

Développer des équipements médicaux et des offres de dispositifs de diagnostic

Dépenses en capital de 15,2 millions de dollars dédiées à l'innovation des dispositifs médicaux en 2022. Le marché mondial des dispositifs médicaux prévoyait de atteindre 603,5 milliards de dollars d'ici 2027.

Créer des solutions de blockchain de santé pour la gestion des données médicales sécurisées

111, Inc. a engagé 6,5 millions de dollars au développement de la technologie blockchain. Le marché de la blockchain des soins de santé devrait atteindre 5,61 milliards de dollars d'ici 2025.

S'aventurer dans les plateformes de technologie d'assurance de soins de santé

Investissement stratégique de 9,3 millions de dollars dans les plateformes d'IsurTech. Le marché de l'assurance maladie numérique devrait atteindre 94,8 milliards de dollars d'ici 2028.

111, Inc. (YI) - Ansoff Matrix: Market Penetration

You're looking at how 111, Inc. (YI) can push harder into its current markets, which is Market Penetration. The numbers from the second quarter of 2025 show where the immediate leverage is.

Increase digital marketing spend, capitalizing on the 53.6% rise in promotional product sales revenue.

The push on marketing promotional products is definitely paying off. In the second quarter of 2025, the sales revenue from these marketing promotional products saw a year-over-year jump of 53.6%. That kind of growth signals that the digital marketing spend you are putting toward upstream partners is hitting the right pharmacies. We should see this as a clear signal to increase that specific budget line item, given the strong return on investment shown in the latest report. It's a direct win in the existing market space.

Deepen the virtual pharmacy network to drive higher volume through the existing 1 Drug Mall B2B platform.

The B2B segment, anchored by the 1 Drug Mall online wholesale pharmacy, is where the majority of 111, Inc. (YI)'s revenue comes from. The strategy here is to extract more volume from the current network. That virtual network currently connects with about 470,000 pharmacies across China. Driving higher transaction frequency or average order value (AOV) through these established B2B relationships is pure market penetration. You don't need new infrastructure, just better utilization of the existing digital connections.

Utilize the 19 fulfillment centers to guarantee 24-hour delivery in over 300 major cities, beating local competitors on speed.

Supply chain speed is a competitive moat, and 111, Inc. (YI) has been building capacity fast. As of the second quarter of 2025, the company operates 19 fulfillment centers. This physical footprint supports the goal of guaranteeing 24-hour delivery across more than 300 major cities. That speed advantage directly attacks the core weakness of traditional, offline competitors who can't match that logistics promise. Here's the quick math: faster delivery means lower customer friction, which should translate directly into higher order volume from existing partners.

Here's a snapshot of the operational scale supporting this penetration push:

Offer loyalty programs via 1 Pharmacy to boost repeat purchases from the B2C consumer base.

The direct-to-consumer channel, 1 Pharmacy, needs a retention focus. The B2C Net Revenue saw a 9.0% decline year-over-year in Q2 2025. To counter this, implementing tiered loyalty programs that reward frequent users of the online retail pharmacy is critical. You want to make the switching cost for a consumer choosing between 1 Pharmacy and a competitor as high as possible through accrued benefits, not just price. If onboarding takes 14+ days, churn risk rises.

Aggressively price key over-the-counter (OTC) drugs to capture market share from traditional, offline pharmacies.

The broader OTC market is massive, valued at USD 195.96 billion in 2025 globally. In the offline world, retail chain pharmacies still hold the largest slice, capturing 42.4% of turnover in 2024. Your competitive move is to use your digital efficiency to undercut those offline prices on high-volume, key OTC drugs. The online pharmacy segment itself is growing at a 10.2% CAGR, so aggressive pricing helps pull market share from the slower-growing offline segment directly into your faster-growing online channel.

Here are the key action drivers for this quadrant:

• Allocate 15% of incremental marketing budget to digital channels showing 53.6% revenue growth.
• Target a 5% increase in transaction frequency across the 470,000 B2B partners.
• Achieve 99% on-time delivery rate within the 300 target cities.
• Launch a loyalty tier offering a 5% discount after the third purchase on 1 Pharmacy.
• Identify the top 10 OTC SKUs and price them 3% below the average price at major retail chains.

Finance: draft 13-week cash view by Friday.

111, Inc. (YI) - Ansoff Matrix: Market Development

You're looking at how 111, Inc. (YI) can push its existing digital and supply chain muscle into new geographic or customer segments. This is Market Development, and the numbers show where the current footprint ends and where the next push needs to go.

The 'MANTIANXING' supply chain project is your current domestic beachhead, having expanded fulfillment centers to 19 locations as of the second quarter of 2025. Remember, in the first quarter of 2025, the plan was already set to add at least 14 more fulfillment centers by the end of 2025, building on the 18 centers operational then. This expansion is critical for reaching those lower-tier Chinese cities you're targeting, especially since Q2 2025 net revenues saw a 6.4% year-over-year decrease, suggesting domestic market penetration is getting tougher.

Still, the digital empowerment of upstream partners is showing traction. Sales revenue from marketing promotional products jumped 53.6% year-over-year in Q2 2025, and the associated customer count grew by 19.0% year-over-year. That's concrete proof the digital channel works when you push it.

Here's a quick look at the scale you're working with as you plan this next move:

Repackaging the S2B2C model (Supply chain to Business to Consumer) for large, private hospital systems means shifting focus from the existing base. Your virtual network currently serves approximately 470,000 pharmacies, which are primarily small to medium-sized entities. The strategic cooperation memorandum of understanding signed with Eli Lilly and Company (LLY) explicitly targets expanding new retail channels such as private hospitals. This is a direct play to move upmarket from the smaller B-side partners.

Launching the 1 Clinic internet hospital services in new, underserved rural regions aims to capture a fresh patient segment. While specific rural penetration numbers aren't public, 1 Clinic already provides cost-effective online consultation, electronic prescription service, and patient management service. This service structure is ideal for regions lacking physical access. The company's Q1 2025 Non-GAAP total operating expenses as a percentage of net income dropped to 5.4% from 5.7% year-over-year, showing efficiency gains that can fund this geographic push.

Forming strategic partnerships with regional government health bureaus is about securing preferred digital distribution status. You already have established relationships, evidenced by the strategic partnership with Eli Lilly and Company (LLY) to become their designated e-prescription platform. Furthermore, 111, Inc. has established strategic partnerships with over 500 renowned domestic and international pharmaceutical companies. This existing relationship depth provides the leverage needed to negotiate preferred status with local health authorities.

To explore low-risk entry into a geographically similar market like Vietnam or Indonesia with the 1 Drug Mall B2B platform, you look at the domestic B2B success. The 1 Drug Mall platform currently provides drug procurement service for more than 93,000 drugstore members. This established B2B transaction volume and supply chain reliability is the core offering you would export. The company's Q1 2025 income from operations was RMB 0.1 million (US$0.02 million), so any international venture needs to be low-capital intensive.

• MANTIANXING fulfillment centers target expansion beyond 19 locations.
• 1 Drug Mall serves over 93,000 drugstore members domestically.
• 1 Clinic offers online consultation and electronic prescription services.
• Q2 2025 marketing promotional product revenue grew 53.6%.
• Partnered with over 500 pharmaceutical companies.

Finance: draft the capital allocation model for the planned 14+ fulfillment centers by Friday.

111, Inc. (YI) - Ansoff Matrix: Product Development

You're looking at how 111, Inc. (YI) plans to drive growth by introducing new offerings into its existing markets. This is the Product Development quadrant of the Ansoff Matrix, building on the infrastructure you already have in place.

The foundation for these new products is the existing platform. For instance, the second quarter of 2025 saw net revenues of US$447.5 million (RMB 3.2 billion), following Q1 2025 revenues of US$486.3 million (RMB 3,529 million). The trailing twelve months revenue as of Q2 2025 stood at RMB 14.18 billion.

Develop new AI-driven diagnostic tools for the 1 Clinic internet hospital, leveraging the company's 28 patents.

• The 1 Clinic already provides online consultation, electronic prescription service, and patient management service.
• The company maintained quarterly operational profitability in Q1 2025.

Expand the SaaS-based 1 Health Membership program to include chronic disease management and remote monitoring services.

• This expansion builds on the existing digital empowerment of the value chain.
• The company achieved positive operating cash flow in Q1 2025, totaling RMB 112.6 million (US$15.5 million).

Introduce a line of high-margin, private-label nutritional supplements and medical devices on the 1 Pharmacy B2C platform.

• The 1 Pharmacy is the online retail pharmacy component.
• In Q2 2025, marketing promotional products related sales revenue increased by 53.6% year-over-year.
• The customer count for these related sales grew by 19.0% year-over-year in Q2 2025.

Create a dedicated data analytics service for pharmaceutical partners, monetizing the vast patient and transaction data.

• 111, Inc. (YI) already provides omni-channel support including data analytics to strategic partners.
• The B2B segment generates the majority of the company's revenue.
• The general agency business model saw monthly sales volume increase to over seven times its Q1 level by Q2 2025.

Integrate online loan application services for small pharmacies using 1 Drug Mall to finance their inventory procurement.

• 1 Drug Mall serves as a one-stop shop for pharmacies to source pharmaceutical products.
• The company's total operating expenses in Q2 2025 were RMB 185.3 million (US$25.9 million).

Here's a quick look at the financial context as of mid-2025:

The focus on new product development is happening while the company is managing costs; total operating expenses as a percentage of net revenues decreased by 30 basis points year-over-year in Q1 2025, settling at 5.5%. Still, the Non-GAAP net loss attributable to ordinary shareholders for Q2 2025 was RMB 16.7 million (US$2.3 million).

Finance: draft 13-week cash view by Friday.

111, Inc. (YI) - Ansoff Matrix: Diversification

Acquire a small, regional health insurance provider to offer integrated digital health plans (new product, new market segment).

The move into integrated digital health plans targets a market where general health insurance Customer Acquisition Cost (CAC) averages between $300 and $900 per customer, depending on the acquisition model. This strategy leverages the existing digital health platform capabilities of 111, Inc. (YI) to cross-sell new insurance products into a new market segment. In the Philippines, where the eHealth market is projected to grow at a Compound Annual Growth Rate (CAGR) of 16.05% from 2025 to 2033, an acquisition could immediately capture a share of the existing USD 8.77 Billion health insurance market from 2024. Inorganic growth via acquisition carries a different cost profile than organic CAC, but the general insurance industry saw inorganic CAC estimated at $207.74 in a rigorous regulatory environment in 2024.

Launch a dedicated B2B logistics and warehousing service for non-pharmaceutical goods, utilizing the existing supply chain infrastructure.

This leverages the operational footprint, which, as of Q2 2025, includes 19 fulfillment centers under the 'MANTIANXING' supply chain project. The target market is the United States Logistics Market, anticipated to reach USD 1,997.6 Billion in 2025. Third-Party Logistics (3PL) providers are projected to dominate this market, with their share of overall industrial leasing activity expected to remain at or near 35% in 2025. The existing infrastructure, which supported 111, Inc. (YI)'s LTM revenue of 14.18B CNY as of Q2 2025, offers immediate scale for non-pharmaceutical goods distribution.

Partner with a US or European biotech firm to co-develop and commercialize a novel drug exclusively for the China market.

This targets the rapidly expanding Chinese biotechnology sector. The China Biotechnology market size reached USD 133.04 Billion in 2025. Specifically, licensing deals for innovative drugs in China surpassed $60 billion in the first half of 2025. Furthermore, Chinese pharmaceutical companies' sales of early-stage assets to global partners soared to nearly US$70 billion as of September 2025. This strategy capitalizes on the trend where R&D spending in China has approached parity with the U.S. in gross domestic spending.

Establish a joint venture in a new country, like the Philippines, to replicate the full S2B2C model from scratch.

Replicating the S2B2C model requires tapping into the digital health ecosystem growth. The Philippines healthcare services industry revenue reached 4.2 billion US dollars in 2024, with a projected CAGR of 9% between 2022-2028. The connected healthcare segment shows a CAGR of 30.1% from 2025-2033, reaching USD 5,412.7 Million by 2033. The total health expenditure in the Philippines reached PHP 1.44 trillion (~USD 26.2 billion) in August 2024. The joint venture would aim to capture a portion of the 44.4% of health expenditures currently paid out-of-pocket by households.

Invest in a specialized medical device manufacturing startup, moving beyond distribution into production.

This shifts 111, Inc. (YI) from distribution to production, a move supported by strong investor sentiment in the sector. Venture investment across the medical device sector in Q1 2025 posted $2.6 billion across 132 deals, a 20% rise compared to the 2024 average capital deployment. The average investment value per funding round in this market exceeds USD 21 million. The total number of investors in this market has surpassed 16K. The company stage data shows over 2,670 early-stage startups are actively developing new technologies. The top investors in the medical devices market have a combined investment value over USD 10.5 billion.

Here's the quick math on the current state:

The Q2 2025 results showed a 6.4% decrease in net revenues year-over-year, but operating expenses fell by 9.3% YoY, while sales revenue from marketing promotional products grew by 53.6%. The co-founders currently beneficially own 42.7% of the total issued share capital.

Potential strategic focus areas for investment allocation include:

• Focus on digital health plan integration for new customer acquisition.
• Utilize existing infrastructure to capture B2B logistics market share.
• Targeting co-development deals in the China biotech space, given the 11.8% projected CAGR for the biopharmaceutical segment through 2030.
• Replicating the S2B2C model in the Philippines, where digital health adoption is accelerating.
• Investing in startups that have mapped their 510(k) pathway, as regulatory rigor is critical for MedTech VCs.